Ovarian Cancer Awareness Month (see related guidelines) Search | National Guideline Clearinghouse

Search | National Guideline Clearinghouse

• Ovarian Cancer Awareness Month (see related guidelines)

1-18 of 18 results for

“Neoplasms”

• GUIDELINE SUMMARY
 
• NGC:008822
 
• 2011 JUL 7 (REAFFIRMED 2016 OCT 31)

Management of a suspicious adnexal mass.

Program in Evidence-based Care

Compare

• GUIDELINE SUMMARY
 
• NGC:009352
 
• 2004 MAY (REVISED 2012 OCT)

Cancer screening.

University of Michigan Health System

Compare

• GUIDELINE SUMMARY
 
• NGC:009250
 
• 1996 (REVISED 2012)

ACR Appropriateness Criteria® staging and follow-up of ovarian cancer.

American College of Radiology

Compare

• GUIDELINE SUMMARY
 
• NGC:010253
 
• 2010 JUL (REVISED 2013 APR)

Epithelial ovarian, fallopian tube, and primary peritoneal cancer.

CancerControl Alberta

Compare

• GUIDELINE SUMMARY
 
• NGC:010887
 
• 2015 NOV 11

Follow-up of patients who are clinically disease-free after primary treatment for fallopian tube, primary peritoneal, and epithelial ovarian cancer.

Program in Evidence-based Care

Compare

• GUIDELINE SUMMARY
 
• NGC:009736
 
• 2007 JUN (REVISED 2013 APR)

NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer.

National Society of Genetic Counselors

Compare

• GUIDELINE SUMMARY
 
• NGC:010895
 
• 2016 JAN 27

Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy.

National Institute for Health and Care Excellence (NICE)

Compare

• GUIDELINE SUMMARY
 
• NGC:009893
 
• 2013 MAY

Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer.

National Institute for Health and Care Excellence (NICE)

Compare

• GUIDELINE SUMMARY
 
• NGC:009674
 
• 1996 (REVISED 2012)

ACR Appropriateness Criteria® clinically suspected adnexal mass.

American College of Radiology

Compare

• GUIDELINE SUMMARY
 
• NGC:010191
 
• 1996 (REVISED 2014 FEB 18)

Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.

U.S. Preventive Services Task Force

Compare

• GUIDELINE SUMMARY
 
• NGC:010080
 
• 2003 OCT (REVISED 2013 NOV)

Management of epithelial ovarian cancer. A national clinical guideline.

Scottish Intercollegiate Guidelines Network

Compare

• GUIDELINE SUMMARY
 
• NGC:006287
 
• 1999 SEP (REVISED 2008 JAN; REAFFIRMED 2012)

Elective and risk-reducing salpingo-oophorectomy.

American College of Obstetricians and Gynecologists

Compare

• GUIDELINE SUMMARY
 
• NGC:010998
 
• 2016 APR 27

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer.

National Institute for Health and Care Excellence (NICE)

Compare

• GUIDELINE SUMMARY
 
• NGC:009894
 
• 2013 MAY

Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer.

National Institute for Health and Care Excellence (NICE)

Compare

• GUIDELINE SUMMARY
 
• NGC:009318
 
• 1996 (REVISED 2012 DEC 18)

Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.

U.S. Preventive Services Task Force

Compare

• GUIDELINE SUMMARY
 
• NGC:010263
 
• 2012 APR (REVISED 2013 APR)

Ovarian germ cell tumours.

CancerControl Alberta

Compare

• GUIDELINE SUMMARY
 
• NGC:009255
 
• 1996 (REVISED 2012)

ACR Appropriateness Criteria® ovarian cancer screening.

American College of Radiology

Compare

• GUIDELINE SUMMARY
 
• NGC:011072
 
• 2016 OCT 1

Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline.

American Society of Clinical Oncology; Society of Gynecologic Oncology